Advocacy Overview

The dental industry comprises businesses that range in size from small family entities through to local operations of large, multinational therapeutic product suppliers. They share common aspirations for the growth of their business, the creation of jobs and the financial sustainability of the dental industry. Naturally, they are bound by a universal commitment to the supply of quality dental products and services. To excel, these businesses will benefit from a robust advocacy program by ADIA on behalf of those members to achieve a considered balance between economic growth that maximises patient safety.

As the peak business organisation representing dental product manufacturers and suppliers, the ADIA is regularly engages with key political decision makers including Departmental staff and members of state and Federal Parliament. This has culminated in the formation of the Parliamentary Friends of the Dental Industry group, comprising Members of Parliament and Senators with an interest in the ongoing success of the dental industry for the good of all Australia.

ADIA's work at a parliamentary level maintains ADIA's status as a recognised source of sound advice and guidance and supports our advocacy for ongoing improvements to the business and political environment in which members conduct their business. ADIA is therefore able to be an effective advocate for the reform objectives set out in ADIA's policy statements.

Underpinning Parliamentary Engagement Principles

ADIA is non-partisan (non-party political)
ADIA provides advice and recommendations that are:
- ADIA demonstrate leadership, will be trustworthy, and will act with integrity
- All donations and memberships are made transparently and in accordance with internal controls

Parliamentary Engagement Objectives

Maintain among parliamentarians ADIA's status as a recognised source of sound advice and guidance
Achieve the reform objectives set out in the ADIA Advocacy Agenda and policy statements
The high levels of access to senior parliamentarians that ADIA enjoys and the ability to achieve lasting reform is the product of a considered strategy that views parliamentarians as an important partner as opposed to a third-party stakeholder. Over many years, ADIA has created an environment where there is a shared interest in ensuring that businesses in the dental industry can grow, create jobs and operate sustainably

ADIA's Parliamentary Roundtable

Australia's dental industry faces a number of challenges arising out of changes from the commercial, technical and regulatory environment as a result of international and domestic influences. To ensure that Australia's political leadership understands the issues face by the dental industry, each year the Australian Dental Industry Association (ADIA) convenes a meeting at Parliament House in Canberra.

This annual meeting allows the ADIA National Executive and key member representatives to meet Parliamentarians and senior bureaucrats in order to share ideas and identify a pathway that allows the dental industry to grow, create jobs and operate sustainably.

Further Information

If you have an interest in ADIA's work at a parliamentary and departmental level to secure the policy reforms that support businesses in the dental industry, for updates subscribe to the Twitter feed @AusDental or follow us on Facebook at www.facebook.com/dental.industry. Alternatively, you can contact the Association via email at advocacy@adia.org.au or by telephone on 1300 943 094.

This information is available for your use under a Creative Commons Attribution 3.0 Australia license, with the exception of the ADIA logo, other images and where otherwise stated.

Changes to the DBA fact sheet on the use and supply of teeth whitening products.

Posted by ADIA on 13 August 2021

The Dental Board of Australia (the Board) has updated its fact sheet on using and supplying teeth whitening products for dental practitioners and this is now available on the Board's website.

The significant points of note are:

Only registered dental practitioners can use and supply high concentration teeth whitening products.
No current laws or regulations limit teeth whitening products to in-clinic use.

The fact sheet gives dental practitioners an overview of the laws and professional obligations that apply when they use teeth whitening products as part of their practice.

Posted in:TGA Industry News

Canberra dental practice fined $266,400

Posted by ADIA on 3 August 2021

Canberra dental practice fined $266,400 for alleged unlawful supply of dental implants and bone grafts

The Therapeutic Goods Administration (TGA) has issued 20 infringement notices to a Canberra-based dental practice totaling $266,400.

The alleged breaches of the Therapeutic Goods Act 1989 (the Act) include the importation and supply of dental implants (medical devices) and bone grafts (biologicals) that are not approved for use in Australia.

It is alleged that the company imported, supplied and implanted medical devices and biologicals in patients that were not entered into the Australian Register of Therapeutic Goods (ARTG).

Under the Act, therapeutic goods must be entered into the ARTG before they can be lawfully supplied in Australia (unless a specific exemption, approval or authority applies).

Implanted therapeutic goods cannot be recalled, therefore the TGA has asked the dentist to notify all affected patients.

The advice to patients contains information about the implanted products and the ongoing management of their implants.

Patients who have concerns should seek advice from a registered dental practitioner.

If you suspect non-compliance in relation to therapeutic goods, you can report illegal or questionable practices online to the TGA.

If you have concerns about health practitioners, notify the Australian Health Practitioner Regulation Agency (AHPRA).

Posted in:TGA Industry News

Invitation to comment: Sterilisation and Substantial changes

Posted by ADIA on 8 May 2020

Invitation to comment: Sterilisation and Substantial changes

The Therapeutic Goods Administration (TGA) is requesting your comments on the following documents regarding Sterilisation and Substantial changes.

Click here to read the Changes affecting TGA issued conformity assessment certificates documentation.

Background
The TGA guidance 'Checklist guidance to supporting data required for adding or changing sterilisation suppliers for TGA conformity assessment applications' provides additional detail on the documentation required for applications relating to sterilisation supplier changes. It is acknowledged that incomplete or inadequately prepared submissions can further lengthen TGA's review process.

Click here for the Guidance checklist for substantial changes to Sterilisation suppliers.

We look forward to your thoughts. Please submit your response to policy@adia.org.au by close of business Monday, 11 May 2020. Feedback will then be compiled and submitted on Wednesday, 13 May 2020.

Posted in:TGA

Invitation to comment: Scope of regulated software-based products

Posted by ADIA on 30 April 2020

Invitation to comment: Scope of regulated software-based products

The Therapeutic Goods Administration (TGA) is requesting your comment on a consultation on a potential exemption or exclusion of certain regulated software-based products (Software as a Medical DeviceSaMD).

Medical device regulations are currently being reformed, including SaMDsuch as smartphone apps that may be used to diagnose and monitor disease. The reforms are also in line with similar changes introduced by regulators internationally, including in the EU.

Background Information
In 2019, the TGA consulted with stakeholders on a proposal to amend the existing regulations in relation to SaMD. Following this consultation, on 12 December 2019, the Therapeutic Goods (Medical Devices) Regulations 2002 were amended to (in part):

a) provide further detail in the essential principles for SaMD including with regard to cyber security; the management of data and information; and requirements relating to development, production, and maintenance; and

b) introduce new classification rules for SaMD for diagnosis or screening; monitoring; or specifying or recommending treatments for a disease or condition; or for providing therapy through the provision of information.

Currently, the amendments apply from 12 December 2019, while the classification rules apply from 25 August 2020 with transitional provisions applying for four years after that date for those sponsors who have ARTG entries prior to 25 August 2020 and who notify the TGA by 25 February 2021.

Please note - these dates are likely to be extended following an EU decision on Monday, 20 April 2020 to delay due to the pandemic.

The TGA is currently developing industry guidance to help sponsors and manufacturers understand how they can demonstrate compliance with the amended regulations. The guidance will be progressively published on the TGA website throughout 2020. You can read the amended regulations here.

Based on feedback to the 2019 consultation, the TGA is now seeking further clarification on the boundary for software-based products that could potentially be exempt or excluded so that sponsors and manufacturers are not subject to unnecessary regulatory burden, for instance, in cases where products present lower risk to safety or where products may already be subject to suitable oversight under other regulatory frameworks.

We look forward to your thoughts on the consultation paper. Please submit your response to policy@adia.org.au by close of business Monday, 11 May 2020. Feedback on the consultation paper will then be compiled and submitted on Wednesday, 13 May 2020.

Posted in:TGA

< Previous | 1 | 2 | 3 | Next >